136 related articles for article (PubMed ID: 10518247)
1. Effect of various salts on the stability of lansoprazole, omeprazole, and pantoprazole as determined by high-performance liquid chromatography.
Ekpe A; Jacobsen T
Drug Dev Ind Pharm; 1999 Sep; 25(9):1057-65. PubMed ID: 10518247
[TBL] [Abstract][Full Text] [Related]
2. Reversed-phase high performance liquid chromatographic method for the determination of lansoprazole, omeprazole and pantoprazole sodium sesquihydrate in presence of their Acid-induced degradation products.
El-Sherif ZA; Mohamed AO; El-Bardicy MG; El-Tarras MF
Chem Pharm Bull (Tokyo); 2006 Jun; 54(6):814-8. PubMed ID: 16755049
[TBL] [Abstract][Full Text] [Related]
3. Stability of pantoprazole in an extemporaneously compounded oral liquid.
Dentinger PJ; Swenson CF; Anaizi NH
Am J Health Syst Pharm; 2002 May; 59(10):953-6. PubMed ID: 12040734
[No Abstract] [Full Text] [Related]
4. Stability of pantoprazole in 0.9% sodium chloride injection in polypropylene syringes.
Johnson CE
Am J Health Syst Pharm; 2005 Nov; 62(22):2410-2. PubMed ID: 16278334
[No Abstract] [Full Text] [Related]
5. Chiral resolution of pantoprazole sodium and related sulfoxides by complex formation with bovine serum albumin in capillary electrophoresis.
Eberle D; Hummel RP; Kuhn R
J Chromatogr A; 1997 Jan; 759(1-2):185-92. PubMed ID: 9050224
[TBL] [Abstract][Full Text] [Related]
6. [Visual documentation of the stability of intravenous solutions of omeprazole (Losec) and pantoprazole (Pantoloc)].
Leitner A; Zöllner P
Wien Med Wochenschr; 2002; 152(21-22):568-73. PubMed ID: 12506681
[TBL] [Abstract][Full Text] [Related]
7. Selective inhibition of the gastric H+,K(+)-ATPase by omeprazole and related compounds.
Lorentzon P; Bayati A; Lee H; Andersson K
Ann N Y Acad Sci; 1997 Nov; 834():592-9. PubMed ID: 9405870
[No Abstract] [Full Text] [Related]
8. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
Andersson T
Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous determination of pantoprazole and its two metabolites in dog plasma by HPLC.
Xie Z; Chen X; Jin F; Zhong D
J Chromatogr Sci; 2005; 43(5):271-5. PubMed ID: 15975247
[TBL] [Abstract][Full Text] [Related]
10. Similarities and differences in the properties of substituted benzimidazoles: a comparison between pantoprazole and related compounds.
Kromer W
Digestion; 1995; 56(6):443-54. PubMed ID: 8536813
[TBL] [Abstract][Full Text] [Related]
11. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Röhss K; Lind T; Wilder-Smith C
Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
[TBL] [Abstract][Full Text] [Related]
12. The H+, K(+)-ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole.
Simon WA; Büdingen C; Fahr S; Kinder B; Koske M
Biochem Pharmacol; 1991 Jul; 42(2):347-55. PubMed ID: 1650212
[TBL] [Abstract][Full Text] [Related]
13. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
Pauli-Magnus C; Rekersbrink S; Klotz U; Fromm MF
Naunyn Schmiedebergs Arch Pharmacol; 2001 Dec; 364(6):551-7. PubMed ID: 11770010
[TBL] [Abstract][Full Text] [Related]
14. Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously.
Freston J; Chiu YL; Pan WJ; Lukasik N; Täubel J
Am J Gastroenterol; 2001 Jul; 96(7):2058-65. PubMed ID: 11467632
[TBL] [Abstract][Full Text] [Related]
15. A comparison of simplified lansoprazole suspension administered nasogastrically and pantoprazole administered intravenously: effects on 24-h intragastric pH.
Täubel JJ; Sharma VK; Chiu YL; Lukasik NL; Pilmer BL; Pan WJ
Aliment Pharmacol Ther; 2001 Nov; 15(11):1807-17. PubMed ID: 11683695
[TBL] [Abstract][Full Text] [Related]
16. Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole.
Takeuchi K; Konaka A; Nishijima M; Kato S; Yasuhiro T
J Gastroenterol Hepatol; 1999 Mar; 14(3):251-7. PubMed ID: 10197495
[TBL] [Abstract][Full Text] [Related]
17. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs.
Meyer UA
Eur J Gastroenterol Hepatol; 1996 Oct; 8 Suppl 1():S21-5. PubMed ID: 8930576
[TBL] [Abstract][Full Text] [Related]
18. High-performance liquid chromatography method for the quantification of pantoprazole in human plasma.
Ramakrishna NV; Vishwottam KN; Wishu S; Koteshwara M
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Aug; 822(1-2):326-9. PubMed ID: 16005696
[TBL] [Abstract][Full Text] [Related]
19. Spectrophotometric determination of omeprazole, lansoprazole and pantoprazole in pharmaceutical formulations.
Wahbi AA; Abdel-Razak O; Gazy AA; Mahgoub H; Moneeb MS
J Pharm Biomed Anal; 2002 Nov; 30(4):1133-42. PubMed ID: 12408904
[TBL] [Abstract][Full Text] [Related]
20. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
Li XQ; Andersson TB; Ahlström M; Weidolf L
Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
